Takeda Pharmaceutical Co. Ltd. seems to be upbeat about the prospects for its pioneering NEDD8-activating enzyme inhibitor pevonedistat (TAK-924) after presenting new Phase II data on its combination use in higher-risk myelodysplastic syndromes (HR-MDS).
ASCO 2020: Pevonedistat Shows Promise In Higher-Risk MDS
Remission Rates Double At Phase II
Takeda is confident about the promise of its first-in-class molecule for higher-risk myelodysplastic syndromes after positive Phase II data.
